CDR-Life Inc. has announced FDA clearance of an IND application for CDR-404, its lead program in development as a precision immunotherapy for solid tumors.
What had been viewed as a major catalyst for Gilead Sciences Inc. going into 2024 turned into a disappointment on the stock market, as antibody-drug conjugate Trodelvy (sacituzumab govitecan) failed to meet the overall survival primary endpoint in the phase III Evoke-01 study in previously treated metastatic non-small-cell lung cancer (NSCLC).
PDC*line Pharma SA has received €4.7 million (US$5.1 million) in public funding as part of a €12.5 million project to apply its allogeneic leukemia-derived dendritic cell line in the development of personalized vaccines for treating colorectal cancer.
Researchers at Mayo Foundation for Medical Education and Research (MFMER) and University of Nebraska have described proteolysis targeting chimeric (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to a hepatocyte growth factor receptor (HGFR; MET)-targeting moiety through a linker reported to be useful for the cancer.
Medshine Discovery Inc. has identified EGFR (del19/Thr790Met/Cys797Ser triple mutant) inhibitors reported to be useful for the treatment of non-small-cell lung cancer (NSCLC).
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are one of the major advances for non-small-cell lung cancer (NSCLC) management in recent years.
Bridgebio Pharma Inc. has obtained FDA clearance for its IND application for BBO-8520, a first-in-class orally bioavailable and potent small-molecule direct inhibitor of KRAS G12C (ON) state. The company expects to begin enrolling patients with KRAS G12C mutant non-small-cell lung cancer (NSCLC) in the first half of this year.
Allorion Therapeutics Inc. has entered into an exclusive option and global license agreement with Astrazeneca plc to develop and commercialize a novel epidermal growth factor receptor (EGFR) L858R mutated allosteric inhibitor.
Obi Pharma Inc. has received FDA clearance for its IND application to conduct a phase I/II study of OBI-992, a novel antibody-drug conjugate (ADC) cancer therapy targeting TROP2. The trial will open shortly and aims to enroll patients with advanced solid tumors, including non-small-cell lung cancer, small-cell lung cancer and gastric cancer, although several other cancers are also potential targets.
